Spago Nanomedical
0,254SEKVær den første som følger denne virksomhed
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Omsætning
1,05 mio.
EBIT %
-3.759,05 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPAGO
Daglig lav / høj pris
-
Markedsværdi
23,1 mio. SEK
Aktieomsætning
-
Volumen
-
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Peter Lindell | 20,3 % | 20,3 % |
| Avanza Pension | 6,9 % | 6,9 % |
Premium
Not activated
This content is for our Premium customers only.
ViserAlle indholdstyper